Edward S. Park, Ph.D., M.S.

Edward S. Park, Ph.D., is the Founder and President of NeuroReserve. Ed has over 15 years of experience in the research and development (R&D) of biopharmaceuticals, medical devices, and nutritional therapeutics. Most importantly, his father struggled with Parkinson’s disease and dementia for almost two decades before passing away. The impact this experience on his family, which is similar to the experiences faced by so many others today, is the motivation for NeuroReserve.

Before NeuroReserve, Ed led development of nutrition-enabling therapeutics for people with severe under-nourishment caused by cystic fibrosis, short bowel syndrome, pancreatic cancer, and preterm birth. At Alcresta Therapeutics, he successfully directed the end-to-end R&D, testing, regulatory approval (U.S. F.D.A. and E.U.), and launch of RELiZORB, the first-of its-kind combination-enzyme-cartridge to support absorption of critical long-chain polyunsaturated fats for the most malnourished populations.

Earlier, Ed worked with major pharmaceutical and health care companies as an R&D advisor with PricewaterhouseCoopers (PwC) Health Industries Advisory, charting development paths for vaccines, cancer therapeutics, clinical genomics operations, and in vitro diagnostics. Before PwC, Ed worked at Altus Pharmaceuticals (later Alnara Pharmaceuticals) in its commercial and development teams, where he led evaluation of early- and clinical-stage therapeutics for rare diseases, pediatric growth failure, hyperoxaluria and kidney stones, and chronic pancreatitis. Ed started his therapeutics career as an R&D associate at Bristol Myers Squibb.

Ed holds a Ph.D. in chemical-biomolecular engineering from the Georgia Institute of Technology, where he was awarded a U.S. Department of Defense – National Defense Science and Engineering Graduate (NDSEG) Fellowship, sponsored by the Office of Naval Research. He also holds a M.S. and M.B.A. from the Massachusetts Institute of Technology.